Aquestive Therapeutics Announces Two Encore Poster Presentations Highlighting Positive PK And PD Data From Clinical Studies For Anaphylm™ (Epinephrine) Sublingual Film At The Eastern Allergy Conference From May 30 To June 2

5/28/24 8:31:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AQST alert in real time by email

Get the next $AQST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AQST

Date	Price Target	Rating	Analyst
5/10/2024	$8.00	Outperform	Leerink Partners
4/11/2024	$10.00	Overweight	Piper Sandler
3/28/2024	$7.00	Outperform	Raymond James

More analyst ratings

$AQST
Press Releases

Fastest customizable press release news feed in the world

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channelsFinished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on November 5, 2024 WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
11/4/24 4:36:01 PM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injectionData demonstrates Anaphylm offers a consistent and permissive method of drug delivery in anaphylaxis management WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm™ (epinephrine)
10/25/24 8:00:00 AM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration Pharmacokinetic (PK) profile after allergen exposure comparable to non-allergen PK profileOn track for a pre-NDA meeting on Anaphylm in Q4 2024 WARREN, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ (epinephrine) Sublingual Film
10/24/24 8:00:00 AM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care

$AQST
Financials

Live finance-specific insights

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channelsFinished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on November 5, 2024 WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
11/4/24 4:36:01 PM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2024 and provide an update on recent developments in its business after market close on Monday, November 4, 2024. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 5, 2024. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
10/21/24 8:00:00 AM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDAExpanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024Anticipates holding epinephrine prodrug technology investor day in the coming monthsFinishes the second quarter 2024 with cash and cash equivalents of approximately $90 million and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on August 7, 2024 WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:
8/6/24 4:22:19 PM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care

$AQST
Leadership Updates

Live Leadership Updates

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public
6/18/24 8:00:00 AM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
4/1/24 8:00:00 AM ET
$AQST
$EBS
$GMDA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N
6/29/23 8:42:55 AM ET
$AQST
Biotechnology: Pharmaceutical Preparations
Health Care

Aquestive Therapeutics Announces Two Encore Poster Presentations Highlighting Positive PK And PD Data From Clinical Studies For Anaphylm™ (Epinephrine) Sublingual Film At The Eastern Allergy Conference From May 30 To June 2

Chat with this insight

Recent Analyst Ratings for $AQST

$AQST Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Chief Innovation/Tech Officer Schobel Alexander Mark covered exercise/tax liability with 9,645 shares, decreasing direct ownership by 0.97% to 980,726 units (SEC Form 4)

Amendment: Chief Science Officer Wargacki Stephen covered exercise/tax liability with 19,505 shares, decreasing direct ownership by 7% to 261,414 units (SEC Form 4)

Amendment: President and CEO Barber Daniel covered exercise/tax liability with 56,824 shares, decreasing direct ownership by 6% to 826,478 units (SEC Form 4)

$AQST Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Aquestive Therapeutics with a new price target

Piper Sandler initiated coverage on Aquestive Therapeutics with a new price target

Raymond James initiated coverage on Aquestive Therapeutics with a new price target

$AQST FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$AQST Market Insights

Live Market Insights

FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics Releases Topline PK Data From Self-Administration Study Of Anaphylm; Meets Primary Endpoints With Comparable PK Whether Administered By Subjects Or HCPs; Final OAS Challenge Study Enrolling; Pre-NDA Meeting Anticipated By End Of Q3 2024

JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target

Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows

$AQST Press Releases

Fastest customizable press release news feed in the world

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

$AQST Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Aquestive Therapeutics Inc.

SEC Form SC 13G filed by Aquestive Therapeutics Inc.

SEC Form SC 13G/A filed by Aquestive Therapeutics Inc. (Amendment)

$AQST Financials

Live finance-specific insights

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

$AQST SEC Filings

Aquestive Therapeutics Inc. filed SEC Form 8-K: Leadership Update

Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Aquestive Therapeutics Inc.

$AQST Leadership Updates

Live Leadership Updates

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

Recent Analyst Ratings for
$AQST

$AQST
Insider Trading

$AQST
Analyst Ratings

$AQST
FDA approvals

$AQST
Market Insights

$AQST
Press Releases

$AQST
Large Ownership Changes

$AQST
Financials

$AQST
SEC Filings

$AQST
Leadership Updates